Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.39 |
| ▸ | HTR3A | P46098 | 5/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TAF1 | P21675 | 1/20 | 0.37 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3761902 | 0.91 | HTR6 (0.40) | HTR6BRD4TAF1CECR2MAPT | |
| Trifluoroacetic Acid SCHEMBL3749336 | 0.82 | HTR6 (0.39) | HTR6BRD4TAF1CECR2MAPT | |
| Trifluoroacetic Acid SCHEMBL3754067 | 0.79 | HTR6 (0.51) | HTR6KCNH2SMO | |
| Trifluoroacetic Acid SCHEMBL3752555 | 0.78 | HTR6 (0.45) | HTR6CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL3750563 | 0.75 | HTR6 (0.38) | HTR6MAPTHTT | |
| SCHEMBL3752558 | 0.73 | HTR6 (0.37) | HTR6MAPTCYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL3754269 | 0.72 | HTR6 (0.49) | HTR6BRD4TAF1CECR2MAPT | |
| Trifluoroacetic Acid SCHEMBL3759250 | 0.72 | HTR6 (0.49) | HTR6CYP3A4CYP2D6SMO | |
| Trifluoroacetic Acid SCHEMBL3749084 | 0.71 | HTR6 (0.66) | HTR6MAPTHTT | |
| Trifluoroacetic Acid SCHEMBL3744507 | 0.71 | HTR6 (0.39) | HTR6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838518-B2 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| EP-1476151-B1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORGANON NV (NL) | 2008-07-16 | — | — | EP | disclosed |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | MERCK SHARP & DOHME B.V. (NL) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | TPH1, HTR1A, HTR1D | HTR6 12/4885HTR3A 5/4885BRD4 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.